ClinicalTrials.gg

Program

KP-100IT

A development code.

Its studies are mostly in Spinal Cord Injuries, led by Kringle Pharma.

Furthest: phase 3, since Jul 12, 20203 company-led studies, 1 open or runningNext primary completion: Dec 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kringle Pharma31 open or runningphase 3since Jul 12, 2020Jun 27, 2014Dec 31, 2028phase 3 · NCT07722962

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 27, 2014First study: phase 2 study in Spinal Cord InjuriesFirst studyNCT02193334 · 45 enrolled · Japan
  2. Jul 12, 2020Phase 3 study in Deafness, Autosomal Recessive 39NCT04475224 · 25 enrolled · Japan
  3. Jul 20, 2026Phase 3 study in Deafness, Autosomal Recessive 39NCT07722962 · 10 planned · Japan

Ahead

  1. Dec 31, 2028Primary completion: phase 3 study in Deafness, Autosomal Recessive 39NCT07722962

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07722962Deafness, Autosomal Recessive 39 · Japan3Not yet recruitingDec 31, 202810
NCT04475224Deafness, Autosomal Recessive 39 · Japan3UNKNOWNDec 31, 202225
NCT02193334Spinal Cord Injuries · Japan2CompletedDec 21, 201745

How it is read

Names in the registry

  • “KP-100IT”, 3 entries

Codes read as this program: KP100IT.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.